Cargando…

Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study

BACKGROUND: Platinum-based drugs are used as cancer chemotherapeutics for the last 40 years. However, drug resistance and nephrotoxicity are the major limitations of the use of platinum-based compounds in cancer therapy. Platinum (IV) complexes are believed to act as platinum prodrugs and are able t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ratzon, Einav, Najajreh, Yousef, Salem, Rami, Khamaisie, Hazem, Ruthardt, Martin, Mahajna, Jamal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763415/ https://www.ncbi.nlm.nih.gov/pubmed/26906901 http://dx.doi.org/10.1186/s12885-016-2182-8

Ejemplares similares

Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism
por: Khateb, Mamduh, et al.
Publicado: (2012)

Ectopic Expression of Snail and Twist in Ph+ Leukemia Cells Upregulates CD44 Expression and Alters Their Differentiation Potential
por: Kidan, Noa, et al.
Publicado: (2017)

2-Hydroxyestradiol Overcomes Mesenchymal Stem Cells-Mediated Platinum Chemoresistance in Ovarian Cancer Cells in an ERK-Independent Fashion
por: Khamaisi, Hazem, et al.
Publicado: (2022)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
por: Mian, Afsar Ali, et al.
Publicado: (2021)

Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells
por: Regev, Ofer, et al.
Publicado: (2020)

Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates
por: Novohradsky, Vojtech, et al.
Publicado: (2017)

Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion
por: Koren Carmi, Yifat, et al.
Publicado: (2020)

Secreted Soluble Factors from Tumor-Activated Mesenchymal Stromal Cells Confer Platinum Chemoresistance to Ovarian Cancer Cells
por: Koren Carmi, Yifat, et al.
Publicado: (2023)

Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts
por: Ricci, Francesca, et al.
Publicado: (2019)

A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance
por: Fronik, Philipp, et al.
Publicado: (2022)

Identification of Cisplatin-Binding Proteins Using Agarose Conjugates of Platinum Compounds
por: Karasawa, Takatoshi, et al.
Publicado: (2013)

Inbuilt Mechanisms for Overcoming Functional Problems Inherent in Hepatic Microlobular Structure
por: Cohen, Robert D., et al.
Publicado: (2011)

Overcoming Limitations Inherent in Sulfamidase to Improve Mucopolysaccharidosis IIIA Gene Therapy
por: Chen, Yonghong, et al.
Publicado: (2018)

Inhibition of Type IV Secretion Activity and Growth of Helicobacter pylori by Cisplatin and Other Platinum Complexes
por: Lettl, Clara, et al.
Publicado: (2020)

Signaling pathways have an inherent need for noise to acquire information
por: Azpeitia, Eugenio, et al.
Publicado: (2020)

Dibromidodimethyldipyridineplatinum(IV)
por: Kelly, Mairéad E., et al.
Publicado: (2008)

Comparison of Intracellular Stress Response of NCI-H526 Small Cell Lung Cancer (SCLC) Cells to Platinum(II) Cisplatin and Platinum(IV) Oxoplatin
por: Hamilton, Gerhard
Publicado: (2014)

Inherent and Acquired Resistance to Paclitaxel in Hepatocellular Carcinoma: Molecular Events Involved
por: Meena, Avtar Singh, et al.
Publicado: (2013)

Platinum(IV)-Loaded Degraded Glycol Chitosan as Efficient Platinum(IV) Drug Delivery Platform
por: Lerchbammer-Kreith, Yvonne, et al.
Publicado: (2023)

Synthesis and characterization of novel bis(carboxylato)dichloridobis(ethylamine)platinum(IV) complexes with higher cytotoxicity than cisplatin
por: Varbanov, Hristo, et al.
Publicado: (2011)

Platinum nanoparticles: an exquisite tool to overcome radioresistance
por: Li, Sha, et al.
Publicado: (2017)

Ovarian Cancer—Insights into Platinum Resistance and Overcoming It
por: Havasi, Andrei, et al.
Publicado: (2023)

Potent Chlorambucil-Platinum(IV) Prodrugs
por: Aputen, Angelico D., et al.
Publicado: (2022)

Mesoporous Silica Nanoparticles Enhance the Anticancer Efficacy of Platinum(IV)-Phenolate Conjugates in Breast Cancer Cell Lines
por: Predarska, Ivana, et al.
Publicado: (2022)

CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3Kα Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma
por: Remer, Eric, et al.
Publicado: (2020)

The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin
por: Kvardova, Veronika, et al.
Publicado: (2010)

Synthesis, Characterization and Biological Investigation of the Platinum(IV) Tolfenamato Prodrug–Resolving Cisplatin-Resistance in Ovarian Carcinoma Cell Lines
por: Barth, Marie-Christin, et al.
Publicado: (2023)

Triple action Pt(iv) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance
por: Petruzzella, Emanuele, et al.
Publicado: (2018)

Opto‐Electrical Properties of Group IV Alloys: The Inherent Challenges of Processing Hydrogenated Germanium
por: de Vrijer, Thierry, et al.
Publicado: (2022)

Platinum(IV) Complexes of trans-1,2-diamino-4-cyclohexene: Prodrugs Affording an Oxaliplatin Analogue that Overcomes Cancer Resistance
por: Papadia, Paride, et al.
Publicado: (2020)

Cisplatin for cancer therapy and overcoming chemoresistance
por: Ranasinghe, Ranmali, et al.
Publicado: (2022)

In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
por: Mellish, K. J., et al.
Publicado: (1993)

Biomaterial Approaches to Enhancing Neurorestoration after Spinal Cord Injury: Strategies for Overcoming Inherent Biological Obstacles
por: Siebert, Justin R., et al.
Publicado: (2015)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020)

Platinum drugs and taxanes: can we overcome resistance?
por: Sazonova, Elena V., et al.
Publicado: (2021)

Revisiting Platinum-Based Anticancer Drugs to Overcome Gliomas
por: Jeon, Jaewan, et al.
Publicado: (2021)

Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes.
por: Loh, S. Y., et al.
Publicado: (1992)

Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy
por: Zhao, Chong, et al.
Publicado: (2016)

Overcoming inherent problems of preference-based techniques for measuring health benefits: An empirical study in the context of kidney transplantation
por: Kontodimopoulos, Nick, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_7d8ddpg09bt1jbofhauud5i2d6